Cerus (CERS) announces a secondary offering for an undisclosed amount. The company anticipates using the net proceeds for clinical development and other R&D and marketing activities related to its Intercept Blood System, plus other general corporate purposes. CERS may also use a portion of the net proceeds from the offering to prepay the remaining outstanding indebtedness under its growth capital loan with Comerica Bank. Cowen is acting as sole book-runner. Shares -0.5% AH.